Impact of the Thr789Ala variant of the von Willebrand Factor levels, on ristocetin co-factor and collagen binding capacity and its association with coronary heart disease in patients with diabetes mellitus type 2

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 10, 2005, Pages 568-572

  Klemm, T ^a   Mehnert, A K ^a   Siegemund, A ^a   Wiesner, T D ^a   Gelbrich, G ^a   Bluher M ^a   Paschke, Ralf ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

CHD; Thr789Ala variant; Type 2 diabetes; vWF

Indexed keywords

COLLAGEN; RISTOCETIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; COLLAGEN; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEIN BINDING; RISTOCETIN; THREONINE; VON WILLEBRAND FACTOR;

EID: 29144451378     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-872896     Document Type: Article

References (22)

1. Ballard DJ, Humphrey LL, Melton LJ 3rd. Epidemiology of persistent proteinuria in typ II diabetes mellitus. Population based study in Rochester Minnesota. Diabetes 1998; 37: 405-412
2. Blüher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes. Diabetologia 2002; 45: 210-216
3. Caprio S, Wong S, Alberti KGMM. Cardiovascular complications of diabetes. Diabetologia 1997; 40: B78-B82
4. Carr ME. Diabetes mellitus A hypercoagulable state. Journal of Diabetes and its Complications 2001; 15: 44-45
5. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-983
6. The Expert Committee on the Diagnosis and Classification of Diabetes mellitus. Report the Expert Committee on the Diagnosis and Classification of Diabetes mellitus (Committee Report). Diabetes Care 1998; 21 (Suppl 1): S5-S19
7. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality form coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
8. Hopfner RL, Gopalakrishnan V. Endothelin: emerging role in diabetic vascular Complications. Diabetologia 1999; 42: 1383-1394
9. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 3071-3078
10. Jansson JH, Nilsson TK, Johnson O. A novel risk factor for recurrent myocardial infarction and death. British Heart Journal 1991; 66: 351-355
11. Kunkel GR, Graham JB, Fowlkes DM, Lord ST. Rsa I polymorphism in von Willebrand factor (vWF) at codon 789. Nucl Acids Res 1990; 18: 7467
12. Lacquemant C, Gaucher C, Delorme C, Chatellier G, Gallois Y, Rodier M, Passa P, Balkau B, Mazurier C, Marre M, Froguel P. For the GENEDIAB Study Group, and the DESIR Study Group: Association between high von Willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type 1 diabetes. Kidney Int 2000; 57: 1437-1443
13. Leurs PB, Stolk RP, Hamulyak K, Van Oerle R, Grobbee DE, Wolffenbuttel BH. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 2002; 25: 1340-1345
14. Lip G, Blann A. Von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997; 34: 255-265
15. Panzram G. Mortality and survival in Type 2 (non insulin dependent) diabetes mellitus. Diabetologia 1987; 30: 123-131
16. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type II (non-insulin dependent) diabetes mellitus. Diabetologia 1990; 33: 438-443
17. Rossing P, Rossing K, Jacobsen P. Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes 1995; 44: 739-743
18. Schiekofer S, Balletshofer B, Andrassy M, Bierhaus A, Nawroth PP. Endothelial dysfunction in diabetes mellitus. Semin Thromb Hemost 2000; 26: 503-511
19. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility to diabetic nephropathy. New Engl J Med 1989; 320: 1161-1165
20. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hörmann A, Holle R. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39: 1540-1545
21. Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, Shibata A. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992; 42: 32-39
22. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641